In short
This article summarizes clinical trials investigating pneumococcal vaccines containing the serotype 22F, which is one of the pneumococcal polysaccharides included in newer pneumococcal conjugate vaccines. These trials aim to evaluate the safety, immune responses, and effectiveness of vaccines with serotype 22F in preventing pneumococcal disease in different populations, including healthy adults and those at increased risk. The studies examine various aspects such as antibody responses, vaccine efficacy against pneumonia, and comparisons to existing pneumococcal vaccines.
At a glance
- Populations Studied
- Healthy adults 65+, adults 18-64 at increased risk, children and adolescents with risk factors
- Vaccine Types
- 20-valent pneumococcal conjugate vaccine (20vPnC), 21-valent pneumococcal conjugate vaccine (V116)
- Main Objectives
- Safety, immunogenicity, effectiveness against pneumococcal disease
- Key Endpoints
- Antibody levels, opsonophagocytic activity, incidence of pneumonia, adverse events
- Comparison Vaccines
- 13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent pneumococcal polysaccharide vaccine (PPSV23)
- Study Designs
- Randomized controlled trials, test-negative design for effectiveness studies
- Follow-up Periods
- Ranging from 30 days post-vaccination to 6 months or longer
What is the pneumococcal polysaccharide serotype 22F vaccine?
The pneumococcal polysaccharide serotype 22F vaccine is a component of newer pneumococcal vaccines designed to protect against pneumococcal disease. It is specifically targeted against the 22F serotype of Streptococcus pneumoniae bacteria. This serotype is one of the additional strains included in newer 20-valent pneumococcal conjugate vaccines like Apexxnar, which provides broader protection compared to older 13-valent vaccines.
Pneumococcal disease refers to any infection caused by Streptococcus pneumoniae bacteria. These infections can range from mild to severe and include pneumonia, meningitis, and bloodstream infections. Pneumococcal vaccines aim to prevent these potentially serious diseases.
How does it work?
The pneumococcal polysaccharide serotype 22F vaccine works by stimulating the body's immune system to produce antibodies against the outer coating (polysaccharide) of the 22F strain of pneumococcus bacteria. In the Apexxnar vaccine, this polysaccharide is chemically attached (conjugated) to a carrier protein called CRM197 and adsorbed onto aluminum phosphate.
This conjugation process enhances the immune response, especially in young children. When vaccinated individuals are later exposed to the 22F pneumococcal strain, their immune system recognizes it and can respond quickly to prevent infection.
Who should get this vaccine?
The pneumococcal polysaccharide serotype 22F vaccine, as part of broader pneumococcal vaccines, is generally recommended for:
- Adults aged 65 years and older
- Adults aged 18-64 with certain chronic medical conditions or risk factors
- Children and adolescents with increased risk of pneumococcal disease
Specific risk factors that may warrant vaccination include:
- Chronic heart, lung, or liver disease
- Diabetes
- Chronic kidney disease
- Weakened immune system
- Cochlear implants
- Cerebrospinal fluid leaks
How effective is it?
Studies are ongoing to evaluate the effectiveness of newer pneumococcal vaccines containing the 22F serotype. Early research suggests that including this serotype provides additional protection against pneumococcal disease caused by the 22F strain.
One study found that a 20-valent pneumococcal conjugate vaccine (which includes serotype 22F) was effective in preventing vaccine-type community-acquired pneumonia in adults aged 65 and older. However, more research is needed to determine the specific contribution of the 22F component to overall vaccine effectiveness.
Is it safe?
The pneumococcal polysaccharide serotype 22F vaccine, as part of broader pneumococcal vaccines, has been shown to be generally safe and well-tolerated. Common side effects may include:
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
- Muscle pain
- Joint pain
- Fever
Serious allergic reactions are rare but possible. As with any vaccine, healthcare providers monitor for any adverse reactions after administration.
How is it given?
The pneumococcal polysaccharide serotype 22F vaccine is typically administered as part of a broader pneumococcal vaccine. It is given as an intramuscular injection, usually in the upper arm (deltoid muscle) for adults or the thigh for young children. The standard dose is 0.5 mL.
For adults, a single dose is usually sufficient. However, some individuals with certain health conditions may require additional doses or boosters. Your healthcare provider can advise on the appropriate vaccination schedule based on your individual circumstances.
Ongoing research
Research is ongoing to further evaluate the safety, effectiveness, and optimal use of pneumococcal vaccines containing the 22F serotype. Current studies are investigating:
- Long-term effectiveness in preventing pneumococcal disease
- Immune responses in different age groups and populations
- Potential for co-administration with other vaccines, such as influenza vaccines
- Use in children and adolescents at increased risk of pneumococcal disease
These ongoing studies will help refine recommendations for the use of pneumococcal vaccines containing the 22F serotype and potentially expand their use to protect more individuals from pneumococcal disease.